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INTRODUCTION
Jaundice is the most prevalent clinical difficulty of neonates which 
may even lead to brain damage to normal term neonates in severe 
cases [1,2]. The increased production of bilirubin impairment of 
conjugation, decrease in hepatic uptake, and increase in bilirubin 
enterohepatic cycle are some factors contributing to causing 
unconjugated hyperbilirubinaemia [3].
The preferred treatment for this condition in modern medicine 
is phototherapy with blue light. Transfusion exchange may be 
considered as the last way to reduce the bilirubin level in cases 
where jaundice has not shown acceptable response to other 
therapies [4]. Transient erythaematous rash, hyperthermia, loose 
stool, and blood transfusion complications including blood 
transmitted infections, coagulation disorders, thrombocytopenia, 
necrotizing enterocolitis, graft-versus-host disease, electrolyte 
abnormalities, portal vein thrombosis, cardiac arrhythmias, and 
death are some of the side effects of phototherapy [5].
Methods of traditional medicine especially consumption of 
medicinal herbs have been considered by some researchers 
[6,7]. Since ancient times, cotoneaster has been used for the 
treatment of neonatal jaundice in Iran. Cotoneaster is a white 
rather yellow and sweet substance, known as “Purgative manna”, 
from Rosaceae family. This plant has been mentioned in famous 
traditional medicine books such as “Canon of Medicine” by 
Avicenna, “Alhavi” by Rhazes and “Makhzan-ol-Advieh” by Aghili 
Khorasani [8-10]. Although this plant has been traditionally used 
in treating neonatal jaundice, there is a need for more scientific 
study on this issue. In addition, the difficulty in administration can 
be a concern. 
AIm
This study aims to investigate the effect of cotoneaster intake by 
neonates and mothers on the improvement of neonatal jaundice in 
neonates under phototherapy.
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ABSTRACT
Introduction: Consumption of cotoneaster may reduce neonatal 
jaundice. 
Aim: Hence this study was undertaken to determine the effect 
of mothers’ cotoneaster consumption on treatment of their 
neonates’ jaundice.
materials and methods: In this randomized clinical trial study, 
120 neonates with jaundice referred to a hospital in southwest 
Iran were enrolled by nonprobability sampling and divided 
randomly into four groups. In the first group both mothers 
and neonates received cotoneaster; in the second group only 
mothers; in the third group only neonates; and in the fourth group 
the neonates received distilled water as placebo. Phototherapy 
was done under the same condition for all neonates. 
Results: The reduction of bilirubin was significantly higher in 
treatment groups compared to control group (p<0.05). Bilirubin 
in the group of neonates whose mothers consumed cotoneaster 
was less compared to control group at 24 and 36 hours (p<0.05) 
and the highest reduction in bilirubin was observed in the first 
group. The mean duration of hospitalization was longer for the 
control group (p<0.05).
Conclusion: Consumption of cotoneaster by both mothers and 
neonates caused a decrease in neonatal jaundice more rapidly 
compared to other groups and decreased the duration of 
hospitalization. Cotoneaster consumption by mothers, neonates, 
or both may be useful in treatment of neonatal jaundice.
mATeRIAlS AND meThODS
This randomized clinical trial study was conducted on 120 
exclusively breastfeeding neonates with jaundice who were 
hospitalized in Neonatal Unit of Hajar Hospital, Shahrekord, 
Iran in 2010 after obtaining the approval of Ethics Committee of 
Shahrekord University of Medical Sciences (87-8-3) and registering 
in Iran Registry of Clinical Trials (IRCT). Sampling was done by 
nonprobability method. Sample size was determined to compare 
mean bilirubin of each treatment group with control group. The 
sample size formula was used to compare the mean levels between 
two independent samples. By this formula, the sample size is 
determined as , so to detect any difference more 
than 0.75 standard deviation in bilirubin between each treatment 
group and control group, 30 patients were required in each group 
with 95% confidence and 80% power. Then the total sample size 
included 120 patients.
Neonates were assigned into four 30-member groups. In the 
first group both mothers and neonates received cotoneaster; 
in the second group only mothers received cotoneaster; in the 
third group only neonates received cotoneaster; and in the fourth 
group neonates received distilled water as placebo. Phototherapy 
was done under the same condition for all neonates under study. 
Phototherapy cuts had 6 lamps with the wavelength of 420-
460 nm and an average age of less than 2000 hours, and the 
neonates’ distance from the light source was 40 cm. The duration 
of phototherapy was at least four days and the phototherapy was 
performed on the basis of indirect bilirubin levels of higher than 14 
mg/dl [5].
Inclusion criteria
Infants aged 37-42 weeks including pregnancy period with the 
birth weight of 2.5-4 kg and the total bilirubin level of 14-20 mg/
dl who were breastfed and their jaundice began after the second 
Mahmoud Rafieian-Kopaei et al., Cotoneaster and Jaundice www.jcdr.net
Journal of Clinical and Diagnostic Research. 2016 Apr, Vol-10(4): SC01-SC032
[Table/Fig-2]: Comparison of the mean neonatal bilirubin (mg/dl) in the different groups.
Group interval (hour)
12 24 36 48 72
Cotoneaster taken by  mother and infant 13.95 ± 2.31 12.32 ± 2.09 11.50 ± 1.73 11.55 ± 0.79 11.20 ± 0.98
Cotoneaster taken by mother 14.7 ± 2.5 12.23 ± 2.07 11.32 ± 1.57 12 ± 1.23 11.47 ± 0.49
Cotoneaster taken by infant 13.17 ± 2.31 11.01 ± 1.74 11.14 ± 1.47 11.20 ± 1.12 10.75 ± 0.77
Control group 14.88 ± 2.65 13.82 ± 2.03 12.99 ± 1.96 12.06 ± 1.71 11.39 ± 1.55
p-value 0.03 < 0.001 < 0.001 0.59 0.77
[Table/Fig-1]: The mean of direct and total bilirubin (mg/dl) in neonates at 
admission.
Group direct bilirubin Total bilirubin
Cotoneaster taken by  mother and infant 0.53 ± 0.08 16.64 ± 2.81
Cotoneaster taken by mother 0.54 ± 0.16 16.49 ± 2.44
Cotoneaster taken by infant 0.58 ± 0.21 16.21 ± 2.56
Control group 0.51 ± 0.17 15.97 ± 2.91
Overall 0.54 ± 0.16 16.33 ± 2.67
day of life were included. The infants had no previous jaundice in 
life history.
exclusion criteria
Patients with conjugated hyperbilirubinaemia, history of jaundice, 
phototherapy or blood exchange for the previous child, maternal-
infant blood group incompatibility, history of traditional medical 
treatment, any apparent anomaly in the physical examination, 
haematocrit levels of more than 65% or the haemoglobin levels 
of more than 20, and abnormal blood tests (reticulocyte count 
above 5%, disorder in glucose-6 phosphate dehydrogenase 
{G6PD}, positive Coombs test, positive blood smear with respect 
to spherocytosis, ovalocytosis, and elliptocytosis) that indicated 
pathologic jaundice or an underlying disease were excluded.
Treatment and measurements
Infants were given 3 drops/kg of Bilineaster, a cotoneaster drop 
(Barij Essence Pharmaceutical Co., Tehran, Iran) every eight hours 
and their mothers received the drops three times more than their 
neonates.
Total bilirubin, direct bilirubin, blood levels of G6PD, complete 
blood count, blood group, and Rh factor were checked at the 
time of admission, and direct and total bilirubin were measured 
at the beginning of study and 12, 24, 36, 48, and 72 hours after 
admission.
STATISTICAl ANAlySIS
The mean + standard deviation was used for descriptive statistics. 
Chi-square test was used for comparing the categorical variables. 
The normal distribution was evaluated using Kolmogorov test. The 
ANOVA test was used in case of normally distributed variables; 
otherwise, Kruskal-Wallis test was used. The bilirubin levels at the 
beginning of study and 12, 24, and 36 hours after admission were 
normally distributed in each group so the parametric test ANOVA 
was used to compare to compare it between groups, and because 
bilirubin levels at 48 and 72 hour were non-normally distributed, 
the nonparametric test Kruskal-Wallis was used. The parametric 
repeated measures ANOVA was applied to determine whether any 
change exists in bilirubin during the study. Data analysis was done 
by SPSS and p<0.05 was considered as the level of significance.
ReSUlTS
Overall 120 neonates (2 to 23-day-old) with the mean age of 
3.4±6.9 days were enrolled. Forty nine neonates (40.8%) were 
female and the rest were male. For birth order, the infants were 1st-
6th (median: 1) child of family. There was no significant difference 
in gender, history of hospitalization, birth weight, and weight at the 
time of admission among the neonates in different groups (p>0.05). 
Based on ANOVA, there was no statistically significant difference 
in total bilirubin and direct bilirubin at the time of admission among 
the groups (p>0.05) [Table/Fig-1].
Repeated measures ANOVA showed a significant decrease in 
bilirubin level (p<0.05) during the study. In addition, the trend of 
reduction in treatment groups was different based on this test 
(p<0.05). ANOVA showed a significant difference in the bilirubin 
level among the groups at 12, 24, 36, 48 and 72 hours (p<0.05). 
Dunnett’s post-hoc test showed that only the bilirubin level of the 
first group was different from that of the control group at the 12 
hours. At 24 and the 36 hours, the bilirubin level of all treatment 
groups was significantly lower than that of the control group and 
the first group had the lowest bilirubin level in this study. Kruskal-
Wallis test did not show any difference among the groups at 48 
and 72 hours [Table/Fig-2]. The mean duration of hospitalization 
was 70±21.2 hours for the control group and 35.3±15 hours for 
treatment groups with a significant difference (p<0.001).
DISCUSSION
Jaundice is the most prevalent clinical difficulty of neonates which 
may even lead to brain damage to normal term neonates in severe 
cases. Selective treatment of jaundice is phototherapy with blue 
light that was used for treatment for all groups of neonates in the 
present study. At the beginning of this study the total bilirubin 
level of newborn infants was 16.33±2.66 mg/dl that showed the 
necessity of immediate treatment. The difference in the mean 
bilirubin level among the studied groups was not significant at the 
time of admission. However, the total bilirubin at 12, 24, and 36 
hours after the treatment with cotoneaster and phototherapy in the 
studied groups decreased significantly compared to the control 
group that received placebo and phototherapy. 
In addition, the range of hospitalization duration for the studied 
groups was between 12 and 72 (mean: 35.3+15) hours and for the 
control group from 12 to 96 (mean: 70+21.2) hours. The duration 
of hospitalization in the treatment groups was significantly shorter 
than that in the control group. Generally, a significant decrease 
was observed in bilirubin levels during the study in all groups that 
showed the general effect of phototherapy. The results of this 
study confirm the effect of cotoneaster on further reduction of 
bilirubin along with phototherapy. The rate of bilirubin was lower in 
the group that both mothers and neonates received cotoneaster. 
In the present study, the trend of bilirubin reduction was faster in 
the first two days of study compared to the next two days because 
higher levels of bilirubin are more affected by phototherapy and 
cotoneaster. The present study showed that this plant was very 
effective on reducing the neonatal jaundice, which is consistent 
with the studies of Etebari et al., and Azadbakht et al., but is 
inconsistent with Ahmad Shah et al., study [11-13].
To the best of our knowledge few studies have so far examined 
the effect of cotoneaster intake by neonates and/or mothers 
on the improvement of neonatal jaundice in neonates under 
phototherapy. Moreover,  mothers  also underwent the 
administration of cotoneaster in the present study, which led to 
a significant decrease in bilirubin after 24 and 36 hours. After 12 
hours of receiving cotoneaster by mothers the rate of bilirubin 
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did not decrease significantly. However, the effect on reducing 
bilirubin was significant after 24 and 48 hours. This issue strongly 
suggests the probability of excretion of cotoneaster in the breast 
milk; in addition, lack of appropriate blood level of cotoneaster 
because of administering inappropriate doses of medicine may be 
a reason for no effect of cotoneaster used by mothers on reducing 
jaundice in the first 12 hours of treatment compared to the control 
group, which needs more investigation. The effect mechanism of 
cotoneaster is not clear. The major components of cotoneaster 
are manitol, glucose, and sucrose [14]. The laxative effect of 
cotoneaster may increase the frequency of stool and hence the 
excretion of billirubin. But in Ahmad Shah et al., study the frequency 
of defecation and weight of neonates were not different between 
the two groups. In our study we did not determine the billirubin in 
stool of neonates but cotoneaster might increase the excretion of 
billirubin in stool without change in its frequency [13].
There are various herbal medications worldwide for treatment of 
neonatal jaundice. In East Asia, mixture of four plants (Artemisia 
capillaris, Rheum officinale, Scutellaria baicalensis root and 
Gardenia) is used for the treatment of neonatal jaundice. The 
mechanism of its effect is through the activation of hepatic 
receptors that cause the clearance of bilirubin [15]. In order to 
accurately determine the mechanism through which cotoneaster 
plays its role in reduction of the bilirubin, further research is needed. 
However, because of its consumption by mothers and its effect on 
neonatal jaundice, the latter is more probable.
No special side effect was observed after consumption of 
cotoneaster in the present study. Besides, the potential effect 
of cotoneaster on the neonatal jaundice showed that the use of 
cotoneaster by mother could reduce the bilirubin in neonates. 
Since mothers and physicians are worried about administering 
any type of medicine during the neonatal period and the rate 
of bilirubin in the present study reduced after consumption of 
cotoneaster by mothers as with its consumption by neonates, this 
medicine could be recommended to be taken by mothers in case 
of neonatal jaundice. 
lImITATIONS
Short hospital stay of the studied infants and failure to include 
preterm newborns, and use of phototherapy in addition to 
cotoneaster in case group due to ethical considerations are some 
of the limitations of the present work.
CONClUSION
Based on the results of this study, consumption of cotoneaster 
leads to faster reduction of neonatal jaundice and reduces infants 
hospitalization period. In addition, its consumption by mothers can 
be useful in reduction of neonatal jaundice in neonates who are 
breastfed. However, more research is needed on this issue.
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